Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

801-820 of 847 trials

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteAllergologyDermatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyOncology

Botox for Hidradenitis Suppurativa Treatment

We are studying whether Botox can help reduce symptoms in patients with Hidradenitis Suppurativa. This trial will assess changes in skin condition and patient satisfaction over several months.

Hidradenitis SuppurativaMonitoring phase (IV)≤5 visits Post-Trial Drug Access Standard MedicinesAllergologyDermatology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Partially RemoteEndocrinologyNeurology

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Standard MedicinesOncology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementHepatologyNeurology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard MedicinesOncology

Ravulizumab for Pediatric IgA Nephropathy

We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.

Immunoglobulin A Nephropathy6-12 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard MedicinesNephrologyPediatrics

Refractory Epilepsy: YCJ-01 Cannabis Extract

We are studying a cannabis extract to see if it can help reduce seizures in patients with difficult-to-control epilepsy due to Tuberous Sclerosis Complex. The trial will also assess the safety of this treatment.

Tuberous Sclerosis ComplexRefractory Epilepsy in Tuberous Sclerosis Complex6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Bipolar-I Disorder: KarXT Treatment Study

We are testing a new treatment called KarXT for people experiencing manic episodes in Bipolar-I Disorder. The study aims to see if it helps reduce mania symptoms better than a placebo.

Bipolar Disorder with Mania≤3 monthsConfirmation phase (III)Post-Trial Drug Access Investigational MedicinesPsychiatry

Bipolar-I Disorder: Long-term Safety of KarXT

We are studying the long-term safety and tolerability of KarXT for people experiencing manic episodes in Bipolar-I Disorder. This trial aims to ensure that the treatment is safe for those affected.

Mania and Bipolar DisorderConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementPsychiatry

Multiple Sclerosis: THC/CBD Oral Solution

We are studying an oral solution of THC and CBD for people with multiple sclerosis to see if it helps relieve chronic pain and improve other symptoms. This trial compares the treatment to a placebo to assess its effects.

Chronic Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational MedicinesInternal MedicineNeurology

Milsaperidone for Major Depressive Disorder

We are studying whether adding milsaperidone to current antidepressant therapy can improve symptoms in patients with Major Depressive Disorder. The trial also looks at the safety of this new treatment compared to a placebo.

Major Depressive Disorder≤3 monthsConfirmation phase (III)Post-Trial Drug Access Investigational MedicinesPsychiatry

Generalized Myasthenia Gravis: Descartes-08 Treatment

We are studying a new treatment called Descartes-08 for people with generalized myasthenia gravis. The trial aims to see if it helps improve daily activities and muscle strength compared to a placebo.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational MedicinesNeurology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Partially RemotePulmonology

Platysma Prominence: NT 201 Treatment Study

We are investigating whether NT 201 can safely reduce moderate to severe platysma prominence in adults compared to a placebo. This study aims to find out if this treatment can improve appearance and confidence.

Moderate to Severe Platysma Prominence3-6 monthsConfirmation phase (III)Post-Trial Drug Access Standard MedicinesDermatology

Major Depressive Disorder: NBI-1065845 Treatment Study

We are evaluating a new medication to see if it helps maintain improvement in people with Major Depressive Disorder. This study looks at its effects on depressive symptoms and overall functioning.

Major Depressive DisorderConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemotePsychiatry

Search Clinical Trials in the European Union